Screener
Tango Therapeutics TNGX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Tango Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
FAQ
- What is Tango Therapeutics's EBITDA margin?
- Tango Therapeutics (TNGX) reported EBITDA margin of -202.5% in Q1 2026.
- How has Tango Therapeutics's EBITDA margin changed year-over-year?
- Tango Therapeutics's EBITDA margin increased by 42.1% year-over-year, from -349.8% to -202.5%.
- What is the long-term trend for Tango Therapeutics's EBITDA margin?
- Over 4 years (2021 to 2025), Tango Therapeutics's EBITDA margin has grown at a 11.6% compound annual growth rate (CAGR), from -112.6% to -174.7%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Tango Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude